A research role that developed through field work
Kevin’s research experience began with connected-diabetes systems and expanded into sponsor-side rare-disease development. His CV describes technology design, protocol development, study sponsorship and oversight, training, outpatient support, outcomes analysis, partnership development, and selected principal-investigator responsibilities. The roles varied by study.
The later Ultragenyx work added clinical systems strategy, protocol-development-team participation, digital endpoints, data collection, and regulated operating infrastructure across a portfolio.
Selected documented studies
The early end-to-end wireless diabetes feasibility work ran from June 2002 to November 2003 and connected automated collection, analysis, feedback, and social support. Kevin’s role included technology design, protocol development, sponsorship, oversight, training, support, and presentation of findings.
The Proactive Diabetes Interventions work in 2004–2005 examined automated transfer and support in newly diagnosed children and children beginning insulin-pump therapy, with an additional summer-camp feasibility component. The CV documents technology, protocol, oversight, and support responsibilities.
The 2007–2011 automated diabetes-management trial led to the 2012 Diabetes Care publication. The Texas Medicaid adult type 2 diabetes demonstration pilot lists Kevin as principal investigator from 2009–2011. The Kaiser social-support pilot lists him as co-investigator.
Hospital and academic collaborations
Other CV entries include protocol design, data management, and trial operations for Detemir: Role in Type 1 Diabetes (NCT00564395); partnership and clinical operations for a school-nurse intervention (NCT00340613); partnership and operations in a Baylor pancreatic islet-cell transplantation program (NCT00530686); and operations in a real-time glucose-alert study (NCT00322478).
These identifiers are included as historical references from the CV. The record does not describe Kevin as the principal investigator on every study or as the clinical authority for each therapeutic intervention.
Research governance
Kevin’s BellSouth program account includes establishment of an industry IRB for non-significant-risk investigational-device research. His work connected patient safety, protocol compliance, study procedures, technology operation, and participant support.
At Ultragenyx, quality and validation were embedded in the digital clinical organization, with specialist QA/CSV functions and coordination across clinical, data, and vendor teams. This is a different institutional role from his earlier investigator work, but it draws on the same concern for reliable execution.
Public results and attribution
The Diabetes Care randomized trial, the Kaiser pilot abstract, the Diabetes Spectrum article, and the LC-FAOD disease-monitoring abstract provide identifiable public evidence. Some other projects are documented in Kevin’s CV without a public results link. That distinction is preserved throughout the archive.
The research portfolio supports experience moving between clinical intent and practical execution. It does not imply that all projects were randomized, all planned studies completed, or all program objectives became demonstrated outcomes.
Sources and record basis
- Peer-reviewed researchDiabetes Care · 2012 randomized controlled trial
A 12-month study of 48 children evaluated automated glucose-data collection and family feedback. Kevin McMahon is a co-author. The findings concern the intervention studied; they are not a claim about every later product.
- Conference abstractClinical Medicine & Research · 2010 journal issue and pilot abstract
Contains the Diabetes Social Support Feasibility Pilot Study abstract, including Kevin McMahon in the author group. The link opens the journal issue.
- Authored articleDiabetes Spectrum · Power and Pitfalls of Social Media in Diabetes Care
Kevin L. McMahon’s 2013 article addresses patient information, peer support, clinical workflow, and the risks of unreliable health advice.
- Conference abstractMolecular Genetics and Metabolism · ACMG 2021 supplement, eP029
The LC-FAOD disease-monitoring-program abstract lists Kevin McMahon among its authors. It is a conference abstract in an indexed supplement, not a full outcomes paper.